Biovator and BASF have signed a collaboration agreement for final development of in-vitro test systems, capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.
The company said that to meet the market and regulatory need for in-vitro tests in the pharmaceutical sector, it has signed an agreement to cooperate with AstraZeneca R&D in 2007, which was an extension of earlier collaboration.
Stan Mikulowski, CEO of Biovator, said: “Allergic reactions to compounds are a serious risk in new products that needs to be discovered in the early stages of product development. This collaboration has the potential to open new dimensions in early industrial research that involves testing. The future test product can become an important factor when setting new industry standards.”
Biovator said that in addition to reducing the need for animal testing, in-vitro test methods will be faster and less expensive, while providing more reliable results for the chemical, cosmetic, pharmaceutical and food additive industries.